| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/30/2002 | CN1333781A Benzylglycosylamides as inhibitors of smooth muscle cell proliferation |
| 01/30/2002 | CN1333780A Benzylglycosylmmides as inhibitors of smooth muscle cell proliferation |
| 01/30/2002 | CN1333779A Benzyllactobionamides as inhibitors of smooth muscle cell proliferation |
| 01/30/2002 | CN1333778A Benzylmaltotriosides as inhibitors of smooth muscle cell proliferation |
| 01/30/2002 | CN1333773A Process for preparing N6-substituted deaza-adenosine derivatives |
| 01/30/2002 | CN1333772A Imidazo (4,5-c)-pyridine-4-on-derivatives |
| 01/30/2002 | CN1333766A Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds as factor xainhibitors |
| 01/30/2002 | CN1333757A Quinazoline derivatives as medicaments |
| 01/30/2002 | CN1333756A Crystalline bis [(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl)amino] pyrimidin-5-yl](3R,5S-3,5-dihydroxyhept-6-enoic acid] calcium salt |
| 01/30/2002 | CN1333755A Benzimidazole compounds that are vitronectin receptor antagonists |
| 01/30/2002 | CN1333754A Benzoheterocycles and their use as MEK inhibitors |
| 01/30/2002 | CN1333685A Utilisation of I compound for the prophylaxis and therapy of cerebral ischaemia |
| 01/30/2002 | CN1333338A Papilloma pseudovirus and process for preparing same |
| 01/30/2002 | CN1333057A Injection for treating cerebral thrombus and preparation thereof |
| 01/30/2002 | CN1333047A Yunnan pine nut extract and preparation process and use thereof |
| 01/30/2002 | CN1333038A Medicine tea for treating hypertension and cardiopathy and prescription |
| 01/30/2002 | CN1333032A 复方绞股蓝茶 Compound Gynostemma tea |
| 01/30/2002 | CN1333029A Medicine for treating cardio-cerebro vascular disease |
| 01/30/2002 | CN1333027A Foot bath hypotensor |
| 01/30/2002 | CN1333022A Turtle oil, trionxy oil, composition containing same and usage thereof |
| 01/30/2002 | CN1333020A Biochemical material composition for preventing and treating disease caused by smooth muscle cell contraction in human organ |
| 01/30/2002 | CN1078469C Material for adjusting function of biology |
| 01/29/2002 | US6342596 Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| 01/29/2002 | US6342584 Antiproliferative, anticarcinogenic, antitumor, antiinflammatory, and antimetastasis agents; diabetes, restenosis, rheumatoid arthritis treatment; genetic engineering |
| 01/29/2002 | US6342533 Antidepressants udes for bipolar and attention deficit disorders, hyperactivity, parkinson's disease, epilepsy, eating disorders |
| 01/29/2002 | US6342532 Antiarthritic, hypotensive agents for urogenital and glandular disorders; calcium channels modulators |
| 01/29/2002 | US6342531 Pharmaceutical composition containing a cysteine protease inhibitor for prophylaxis and therapy of brain tissue impairment |
| 01/29/2002 | US6342530 Composition and method for parenteral administration of ibuprofen d,l- or l-lysine salt |
| 01/29/2002 | US6342521 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides |
| 01/29/2002 | US6342512 Sulfonylcarboxamide derivatives, process for their preparation and their use as pharmaceuticals |
| 01/29/2002 | US6342510 Antiinflammatory agents and enzyme inhibitors |
| 01/29/2002 | US6342505 Use of 4-substituted tetrahydropyridines for making medicines acting on TGF-β1 |
| 01/29/2002 | US6342502 Thieno[2,3-d]pyrimidine diones and their use in the treatment of reversible obstructive airways diseases |
| 01/29/2002 | US6342498 Arylpiperazines as serotonin reuptake inhibitors and 5-HT1Dα antagonists |
| 01/29/2002 | US6342495 Cardiovascular disorders |
| 01/29/2002 | US6342357 An isolated mutant dna; for diagnosis and therapy for cardiovascular disorders characterized by prolonation of the qt interval on electrocardiogram and the presence of syncope, seizures and sudden death |
| 01/29/2002 | US6342245 Compositions of lipid lowering agents |
| 01/29/2002 | US6342221 Antibody conjugate compositions for selectively inhibiting VEGF |
| 01/29/2002 | US6342219 As anti-angiogenic and in tumor therapy |
| 01/29/2002 | US6342202 Injecting into blood vessel composition consisting essentially of polyvinyl acetate having molecular weight of at least about 50,000, contrast agent and biocompatible solvent to precipitate polymer and embolize blood vessel |
| 01/29/2002 | CA2216789C Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers |
| 01/29/2002 | CA2145296C Benzenealkanoic acids for cardiovascular diseases |
| 01/29/2002 | CA1341336C Neuropeptide y agonists |
| 01/27/2002 | CA2353768A1 Use of growth hormone secretagogues for improvement of functional health status |
| 01/24/2002 | WO2002006492A1 A novel human soluble secreted endopeptidase (sep) for the treatment of sexual dysunfction |
| 01/24/2002 | WO2002006483A1 Novel physiologically active peptide and use thereof |
| 01/24/2002 | WO2002006466A1 Novel g protein-coupled receptor protein and dna thereof |
| 01/24/2002 | WO2002006462A2 Methylated nucleotide regulation of upa gene expression |
| 01/24/2002 | WO2002006453A2 Regulation of human desc1-like serine protease |
| 01/24/2002 | WO2002006300A2 Mutated pf-4, its fragments and mutated fusion peptides, their analogues, corresponding dna, cdna and mrna sequences and their use for inhibiting angiogenesis |
| 01/24/2002 | WO2002006299A2 Therapeutic uses for aminosterol compounds |
| 01/24/2002 | WO2002006288A1 Tetrahydro-heterocycloazepinyl pyrimidine derivatives |
| 01/24/2002 | WO2002006284A1 Indoloquinazolinones |
| 01/24/2002 | WO2002006271A1 Pyrimidine derivatives |
| 01/24/2002 | WO2002006270A1 Novel 6-heteroarylphenanthridines |
| 01/24/2002 | WO2002006264A1 Lipid-rich plaque inhibitors |
| 01/24/2002 | WO2002006261A1 Tocotrienolquinone cyclisation product with an anti-hypercholesterol effect |
| 01/24/2002 | WO2002006253A1 Valsartan salts |
| 01/24/2002 | WO2002006249A1 Method for producing 1-substituted-1,2,3-triazole derivative |
| 01/24/2002 | WO2002006247A1 Substituted amidoalkyl-uracils as parp inhibitors |
| 01/24/2002 | WO2002006245A1 Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof |
| 01/24/2002 | WO2002006242A2 5-substituted 2-aryl-4-pyrimidinones |
| 01/24/2002 | WO2002006236A1 N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
| 01/24/2002 | WO2002006234A1 Sulfone derivatives, process for their production and use thereof |
| 01/24/2002 | WO2002006232A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| 01/24/2002 | WO2002006231A1 Serotonin reuptake inhibitors |
| 01/24/2002 | WO2002006224A1 Pyrrolidine-2-carboxylic acid hydrazide derivatives for use as metalloprotease inhibitors |
| 01/24/2002 | WO2002006223A1 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| 01/24/2002 | WO2002006222A1 Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme |
| 01/24/2002 | WO2002006215A1 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acid derivates |
| 01/24/2002 | WO2002006213A2 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| 01/24/2002 | WO2002006189A2 Aniline derivatives |
| 01/24/2002 | WO2002005864A1 An implantable or insertable therapeutic agent delivery device |
| 01/24/2002 | WO2002005841A1 Treatment of glycogen storage disease type ii |
| 01/24/2002 | WO2002005840A1 Medicinal compositions for promoting fixation of transplanted cells |
| 01/24/2002 | WO2002005813A2 Method for preventing and/or decreasing amyloid production with polycyclic compounds |
| 01/24/2002 | WO2002005795A2 Pharmaceutical combinations for treatment and prevention of diabetes mellitus |
| 01/24/2002 | WO2002005794A2 Use of fluorescein derivatives for the treatment of diseases responsive to the activation of the cystic fibrosis transmembrane conductance regulator chloride channel |
| 01/24/2002 | WO2002005786A1 Pharmaceutical composition improved in peroral absorbability |
| 01/24/2002 | WO2002005784A1 A medicinal aerosol formulation |
| 01/24/2002 | WO2002005782A2 Stable salts of o-acetylsalicyclic with basic amino acids |
| 01/24/2002 | WO2002005633A1 P300 transgenic animal |
| 01/24/2002 | WO2001064750A3 Modulation of the activity of the endothelial cel surface receptor ecrtp/dep-1 in the regulation of angiogenesis |
| 01/24/2002 | WO2001060814A3 Pyrrole substituted 2-indolinone protein kinase inhibitors |
| 01/24/2002 | WO2001058875A3 Substituted 1,2,3,4- tetrahydroquinoline-2-carboxylic acid derivatives |
| 01/24/2002 | WO2001053324A3 Novel haptotactic peptides |
| 01/24/2002 | WO2001053268B1 Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation |
| 01/24/2002 | WO2001047506A3 Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments |
| 01/24/2002 | WO2001046258A3 Transporters and ion channels |
| 01/24/2002 | WO2001038305A3 Novel il-8 receptor antagonists |
| 01/24/2002 | WO2001036005A3 Targeted delivery of therapeutic and diagnostic moieties |
| 01/24/2002 | WO2001034768A3 15 human secreted proteins |
| 01/24/2002 | WO2001034132A3 Use of an aldosterone antagonist for treating restenosis |
| 01/24/2002 | WO2001032910A3 27 human secreted proteins |
| 01/24/2002 | WO2001032627A8 Process of making substituted pyrazoles |
| 01/24/2002 | WO2001029000A3 Bicyclic and tricyclic amines as modulators of chemokine receptor activity |
| 01/24/2002 | WO2001027107A3 Heterocyclic sodium/proton exchange inhibitors and method |
| 01/24/2002 | WO2001023387A3 CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES |
| 01/24/2002 | WO2001023357A3 Fused cycloheptane and fused azacycloheptane compounds and their use as integrin receptor antagonists |
| 01/24/2002 | WO2001019860A3 Proteins associated with cell differentiation |